One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

The Journal of Headache and Pain 2023 Nov 8;24(1):152. doi: 10.1186/s10194-023-01680-4. M Lanteri-Minet, R Fabre, C Martin, K Pradat, A Alchaar, E Bozzolo, M L Duchene, E K Van Obberghen, A Donnet, D Fontaine Abstract Background: Randomized clinical trials have

Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study

The Journal of Headache and Pain 2023 Nov 8;24(1):151. doi: 10.1186/s10194-023-01683-1. Richard B Lipton, Michel Lanteri-Minet, Elizabeth Leroux, Aubrey Manack Adams, Janette Contreras-De Lama, Michael L Reed, Kristina M Fanning, Dawn C Buse Abstract Background: Individuals with migraine frequently experience pre- and post-headache symptoms. This analysis aimed

Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease

Neurology(R) Neuroimmunology & Neuroinflammation 2023 Aug 22;10(6):e200153.doi: 10.1212/NXI.0000000000200153. Print 2023 Nov. Florent Cluse , Marc Hermier, Genevieve Demarquay, Veronique Rogemond, Martial Mallaret, Juliette Svahn, Antoine Pegat, Jerome Honnorat, Emilien Bernard Abstract Objectives: Anti-IgLON5 disease (IgLON5-D) may present with a bulbar-onset motor neuron disease-like phenotype, mimicking bulbar-onset amyotrophic lateral